Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTSR1 | P30989 | 11/20 | 0.70 |
| ▸ | NTSR2 | O95665 | 5/20 | 0.70 |
| ▸ | NPY1R | P25929 | 1/20 | 0.65 |
| ▸ | SORT1 | Q99523 | 4/20 | 0.65 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.64 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.64 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.64 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.64 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.64 |
| ▸ | NMUR2 | Q9GZQ4 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Neurotensin SCHEMBL29357707 | 1.00 | NTSR1 (0.70) | NTSR1NTSR2NPY1RSORT1OPRD1 | |
| SCHEMBL30102522 | 0.98 | NTSR1 (0.70) | NTSR1NTSR2NPY1RSORT1OPRD1 | |
| SCHEMBL30446151 | 0.94 | NMUR2 (0.67) | NTSR1NTSR2NPY1RNMUR2 | |
| SCHEMBL30957024 | 0.92 | KDM1A (0.61) | NTSR1NTSR2NPY1RSORT1 | |
| Neurotensin SCHEMBL30483709 | 0.92 | KDM1A (0.61) | NTSR1NTSR2NPY1RSORT1 | |
| SCHEMBL29361023 | 0.86 | NTSR1 (0.74) | NTSR1NTSR2SORT1OPRD1OPRM1 | |
| SCHEMBL29402893 | 0.86 | HCRTR1 (0.68) | NTSR1NPY1ROPRD1OPRM1OPRK1 | |
| SCHEMBL31302260 | 0.86 | KDM1A (0.58) | NPY1ROPRD1 | |
| SCHEMBL38650581 | 0.86 | KDM1A (0.62) | NPY1ROPRM1OPRK1NMUR2 | |
| SCHEMBL29930119 | 0.84 | NTSR1 (0.87) | NTSR1NTSR2NPY1RSORT1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025227105-A1 | CLEAVABLE LINKERS WITH TUNABLE HALF-LIVES | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2025-10-30 | — | — | WO | disclosed |
| US-20240269293-A1 | PROTEIN-MACROMOLECULE CONJUGATES AND METHODS OF USE THEREOF | OD THERAPEUTICS LIMITED (CN) | 2024-08-15 | — | — | US | disclosed |
| EP-4313154-A1 | PROTEIN-MACROMOLECULE CONJUGATES AND METHODS OF USE THEREOF | OD Therapeutics Limited (HK) | 2024-02-07 | — | — | EP | disclosed |
| US-20220401561-A1 | PROTEIN-MACROMOLECULE CONJUGATES AND METHODS OF USE THEREOF | AJ SCIENCES (YIXING) CO., LTD (CN) | 2022-12-22 | — | — | US | disclosed |
| WO-2022212362-A1 | PROTEIN-MACROMOLECULE CONJUGATES AND METHODS OF USE THEREOF | BEIJING XUANYI PHARMASCIENCES CO., LTD. (CN) | 2022-10-06 | — | — | WO | disclosed |
| EP-4037715-A1 | PROTEIN-MACROMOLECULE CONJUGATES AND METHODS OF USE THEREOF | Beijing Xuanyi Pharmasciences Co., Ltd. (CN) | 2022-08-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240269293-A1 | PROTEIN-MACROMOLECULE CONJUGATES AND METHODS OF USE THEREOF | CD44, MACROD1, MSN | NTSR1 3864/4885NTSR2 4082/4885NPY1R 4021/4885 |
| US-20220401561-A1 | PROTEIN-MACROMOLECULE CONJUGATES AND METHODS OF USE THEREOF | CD44, SSB, DNPEP | NTSR1 3916/4885NTSR2 4097/4885NPY1R 4034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.